Telomere-driven diseases and telomere-targeting therapies
Open accessThe DOI matches its Crossref record; 147 of the 148 references it cites were found in a registry or an index.
Abstract
Telomeres, the protective ends of linear chromosomes, shorten throughout an individual’s lifetime. Telomere shortening is proposed to be a primary molecular cause of aging. Short telomeres block the proliferative capacity of stem cells, affecting their potential to regenerate tissues, and trigger the development of age-associated diseases. Mutations in telomere maintenance genes are associated with pathologies referred to as telomere syndromes, including Hoyeraal-Hreidarsson syndrome, dyskeratosis congenita, pulmonary fibrosis, aplastic anemia, and liver fibrosis. Telomere shortening induces chromosomal instability that, in the absence of functional tumor suppressor genes, can contribute to tumorigenesis. In addition, mutations in telomere length maintenance genes and in shelterin components, the protein complex that protects telomeres, have been found to be associated with different types of cancer. These observations have encouraged the development of therapeutic strategies to treat and prevent telomere-associated diseases, namely aging-related diseases, including cancer. Here we review the molecular mechanisms underlying telomere-driven diseases and highlight recent advances in the preclinical development of telomere-targeted therapies using mouse models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therapeutic benefits have been observed for AAV-mediated delivery of TERT in animal models of aplastic anaemia, IPF and Alzheimer’s disease164,191.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [191]
Experimental — accuracy not yet measuredIn the citing paper
“Genetic defects in telomere maintenance cause human telomeropathies, including dyskeratosis congenita, aplastic anemia, and pulmonary and liver disease exhibiting multiple progeroid features15.”
From The central role of DNA damage in the ageing process (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982 · cited 3×
“Telomeres shorten progressively throughout an individual’s lifetime (Cawthon et al., 2003; López-Otín et al., 2013; Sanders and Newman, 2013).”
BackgroundSelf-citationSpecific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 3×
“Indeed, ∼90% of human cancers present telomerase activity (Kim et al., 1994).”
BackgroundAutophagy in the Pathogenesis of Disease
Levine, B., & Kroemer, G. (2008) · Cell · doi:10.1016/j.cell.2007.12.018 · Cited by 7,069 · cited 1×
“MC is driven by a complex and poorly understood signaling cascade that antecedes apoptosis, necrosis, senescence, or autophagy (Levine and Kroemer, 2008; Vitale et al., 2011).”
BackgroundTelomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750 · cited 2×
“…to counteract telomere attrition associated with cell division throughout life, and therefore telomeres shorten with age in vitro and in vivo (Harley et al., 1990; Hastie et al., 1990; Lindsey et al., 1991; Collado et al., 2007; Liu et al., 2007; Flores et al., 2008; Marion et al., 2009).”
BackgroundAutophagy and Viruses: Adversaries or Allies?
Dong, X., & Levine, B. (2013) · Journal of Innate Immunity · doi:10.1159/000346388 · Cited by 4,430
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400 · cited 2×
“1 C; Greider and Blackburn, 1985).”
BackgroundShelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056 · cited 1×
“1 C; de Lange, 2005; Martínez and Blasco, 2010, 2011).”
Mammalian Telomeres End in a Large Duplex Loop
Griffith, J. D., Comeau, L., Rosenfield, S., Stansel, R. M., Bianchi, A., Moss, H., & de Lange, T. (1999) · Cell · doi:10.1016/s0092-8674(00)80760-6 · Cited by 2,447 · cited 2×
“1, A and B; Griffith et al., 1999; Doksani et al., 2013).”
BackgroundTelomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108 · cited 1×
“…the study of telomerase-deficient mice, which show premature aging phenotypes in both lowproliferating (heart, brain) and high-proliferating compartments (bone marrow [BM], gut, skin, and testis; Blasco et al., 1997; Lee et al., 1998; Herrera et al., 1999; Leri et al., 2003; Ferrón et al., 2004).”
BackgroundSelf-citationOlovnikov (1973) · doi:10.1016/0022-5193(73)90198-7 · Cited by 1,847 · cited 1×
“…up-regulation of the shelterin complex TRF1 and TRF2 in lung, gastric, breast, and renal cancers, suggesting that their overexpression might confer proliferative advantages to tumor cells (Miyachi et al., 2002; Saito et al., 2002; Nakanishi et al., 2003; Diehl et al., 2011; Pal et al., 2015).”
BackgroundHow Shelterin Protects Mammalian Telomeres
Palm, W., & de Lange, T. (2008) · Annual Review of Genetics · doi:10.1146/annurev.genet.41.110306.130350 · Cited by 1,802
Cellular senescence and the senescent secretory phenotype: therapeutic opportunities
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., & Kirkland, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64098 · Cited by 1,774 · cited 2×
“JCB • Volume 216 • NumBer 4 • 2017876 late during life and secrete factors that influence age-associated diseases (Tchkonia et al., 2013).”
BackgroundAssociation between telomere length in blood and mortality in people aged 60 years or older
Cawthon, R. M., Smith, K. R., O'Brien, E., Sivatchenko, A., & Kerber, R. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12384-7 · Cited by 1,761 · cited 2×
“Telomeres shorten progressively throughout an individual’s lifetime (Cawthon et al., 2003; López-Otín et al., 2013; Sanders and Newman, 2013).”
BackgroundCellular senescence in cancer and aging.
Collado, M., Blasco, M. A., & Serrano, M. (2007) · Cell · doi:10.1016/j.cell.2007.07.003 · Cited by 1,708
Self-citationTelomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650 · cited 2×
“…to counteract telomere attrition associated with cell division throughout life, and therefore telomeres shorten with age in vitro and in vivo (Harley et al., 1990; Hastie et al., 1990; Lindsey et al., 1991; Collado et al., 2007; Liu et al., 2007; Flores et al., 2008; Marion et al., 2009).”
BackgroundWATSON, J. D. (1972) · Nature New Biology · doi:10.1038/newbio239197a0 · Cited by 1,632 · cited 1×
“Telomeres shorten with each cell division as a result of the incomplete replication of linear DNA molecules by conventional DNA polymerases, which is called the end-replication problem (Watson, 1972; Olovnikov, 1973).”
BackgroundTelomeres and human disease: ageing, cancer and beyond
Blasco, M. A. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1656 · Cited by 1,434 · cited 2×
“Thus, telomeres are essential to ensure chromosome stability (Blasco, 2005; Palm and de Lange, 2008).”
BackgroundSelf-citationTelomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357 · cited 2×
“Mutations in telomere genes have been found in up to 25% of familial and 1–3% of sporadic IPF patients (Armanios et al., 2007; Alder et al., 2008; Cogan et al., 2015; Kannengiesser et al., 2015; Stuart et al., 2015; Stanley et al., 2016).”
BackgroundEssential role of mouse telomerase in highly proliferative organs
Lee, H.-W., Blasco, M. A., Gottlieb, G. J., Horner, J. W., Greider, C. W., & DePinho, R. A. (1998) · Nature · doi:10.1038/33345 · Cited by 1,270 · cited 3×
“…the study of telomerase-deficient mice, which show premature aging phenotypes in both lowproliferating (heart, brain) and high-proliferating compartments (bone marrow [BM], gut, skin, and testis; Blasco et al., 1997; Lee et al., 1998; Herrera et al., 1999; Leri et al., 2003; Ferrón et al., 2004).”
BackgroundSelf-citationp53- and ATM-Dependent Apoptosis Induced by Telomeres Lacking TRF2
Karlseder, J., Broccoli, D., Dai, Y., Hardy, S., & de Lange, T. (1999) · Science · doi:10.1126/science.283.5406.1321 · Cited by 1,086 · cited 1×
“In contrast to telomerase inhibition, telomere uncapping has been shown to cause rapid induction of cell death and/or senescence in a manner that is independent of telomerase activity and telomere length (Karlseder et al., 1999; Martínez et al., 2009b).”
BackgroundArmanios, M., & Blackburn, E. H. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3246 · Cited by 982 · cited 5×
“Among the telomere syndromes, IPF is the most common condition associated with telomere dysfunction in humans (see text box; Armanios and Blackburn, 2012).”
BackgroundInfluentialChin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S.-L., Gottlieb, G. J., Greider, C. W., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80762-x · Cited by 979 · cited 5×
“Moreover, these antitumorigenic effects of short telomeres owing to telomerase deficiency are abrogated in the absence of p53 (Chin et al., 1999).”
BackgroundInfluentialTelomeric DNA damage is irreparable and causes persistent DNA-damage-response activation
Fumagalli, M., Rossiello, F., Clerici, M., Barozzi, S., Cittaro, D., Kaplunov, J. M., Bucci, G., Dobreva, M., Matti, V., Beausejour, C. M., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2466 · Cited by 851 · cited 1×
“Shortened telomeres induce a DDR that leads to a growth arrest, during which cells attempt to repair the damage and, if DNA damage is irreparable, triggers replicative senescence (Zou et al., 2004; Fumagalli et al., 2012).”
Mitotic catastrophe: a mechanism for avoiding genomic instability
Vitale, I., Galluzzi, L., Castedo, M., & Kroemer, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3115 · Cited by 834 · cited 1×
“MC is driven by a complex and poorly understood signaling cascade that antecedes apoptosis, necrosis, senescence, or autophagy (Levine and Kroemer, 2008; Vitale et al., 2011).”
BackgroundTelomeres and telomerase in cancer
Artandi, S. E., & DePinho, R. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp268 · Cited by 823 · cited 2×
“…tetraploidization, nonreciprocal translocations, chromothripsis, and kataegis, which promote acquisition of oncogenic mutations and malignant traits required for a fully malignant phenotype (Artandi and DePinho, 2010; Martínez and Blasco, 2010; Davoli and de Lange, 2012; Maciejowski et al., 2015).”
BackgroundShort telomeres are a risk factor for idiopathic pulmonary fibrosis
Alder, J. K., Chen, J. J.-L., Lancaster, L., Danoff, S., Su, S.-C., Cogan, J. D., Vulto, I., Xie, M., Qi, X., Tuder, R. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804280105 · Cited by 805 · cited 2×
“Mutations in telomere genes have been found in up to 25% of familial and 1–3% of sporadic IPF patients (Armanios et al., 2007; Alder et al., 2008; Cogan et al., 2015; Kannengiesser et al., 2015; Stuart et al., 2015; Stanley et al., 2016).”
BackgroundHow stem cells age and why this makes us grow old
Sharpless, N. E., & DePinho, R. A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2241 · Cited by 743 · cited 1×
“Telomere attrition in stem cell compartments impairs their tissue and self-renewal capacity and is considered to be one of the primary molecular causes of aging and the onset of aging-associated diseases (Flores et al., 2005; Sharpless and DePinho, 2007).”
BackgroundTelomerase and cancer therapeutics
Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728 · cited 2×
“Telomeres as therapeutic targets • martínez and Blasco 883 notherapy, gene therapy using telomerase promoter-driven expression of a suicide gene, and chemicals that block telomerase biogenesis (Harley, 2008; Agrawal et al., 2012; Buseman et al., 2012; Jafri et al., 2016).”
BackgroundRoles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
Jafri, M. A., Ansari, S. A., Alqahtani, M. H., & Shay, J. W. (2016) · Genome Medicine · doi:10.1186/s13073-016-0324-x · Cited by 716 · cited 16×
“To date, several mechanisms underlying reactivation of telomerase in cancer cells have been described: notably, mutations in TERT promoter, alterations in the alternative splicing of TERT premRNA, gene amplification, epigenetic changes, alterations in regulatory factors, and /or disruption of TPE (Jafri et al., 2016).”
BackgroundInfluentialChromothripsis and Kataegis Induced by Telomere Crisis
Maciejowski, J., Li, Y., Bosco, N., Campbell, P. J., & de Lange, T. (2015) · Cell · doi:10.1016/j.cell.2015.11.054 · Cited by 675 · cited 2×
“…tetraploidization, nonreciprocal translocations, chromothripsis, and kataegis, which promote acquisition of oncogenic mutations and malignant traits required for a fully malignant phenotype (Artandi and DePinho, 2010; Martínez and Blasco, 2010; Davoli and de Lange, 2012; Maciejowski et al., 2015).”
BackgroundRole of Telomeres and Telomerase in Aging and Cancer
Shay, J. W. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0062 · Cited by 668 · cited 7×
“Telomeres as anticancer targets Given that most tumors (85–90%) present telomerase activity, whereas telomerase is absent in most normal tissues, or is strictly regulated in transient-amplifying stem cells, inhibition of telomerase is an attractive target for cancer therapy (Kim et al., 1994; Shay, 2016).”
BackgroundInfluentialSenescence and immortalization: Role of telomeres and telomerase
Shay, J. W., & Wright, W. E. (2005) · Carcinogenesis · doi:10.1093/carcin/bgh296 · Cited by 610
Bernardes de Jesus, B., Vera, E., Schneeberger, K., Tejera, A. M., Ayuso, E., Bosch, F., & Blasco, M. A. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200245 · Cited by 548 · cited 3×
“2; Bernardes de Jesus et al., 2012; Bär et al., 2014).”
Self-citationYUDKIN, J. (1972) · Nature · doi:10.1038/239197a0 · Cited by 542
Telomere Length in Epidemiology: A Biomarker of Aging, Age-Related Disease, Both, or Neither?
Sanders, J. L., & Newman, A. B. (2013) · Epidemiologic Reviews · doi:10.1093/epirev/mxs008 · Cited by 537
'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally
García‐Cao, I., García‐Cao, M., Martín‐Caballero, J., Criado, L. M., Klatt, P., Flores, J. M., Weill, J., Blasco, M. A., & Serrano, M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf595 · Cited by 529 · cited 2×
“Telomerase-deficient mice show a worsening of phenotypes with increasing mouse generations owing to inherited progressively shorter telomeres, with the later generations showing severe phenotypes and premature death at pre-reproductive ages (Lee et al., 1998; Herrera et al., 1999; García-Cao et al., 2002).”
BackgroundSelf-citationSuper-Resolution Fluorescence Imaging of Telomeres Reveals TRF2-Dependent T-loop Formation
Doksani, Y., Wu, J. Y., de Lange, T., & Zhuang, X. (2013) · Cell · doi:10.1016/j.cell.2013.09.048 · Cited by 493 · cited 2×
“1, A and B; Griffith et al., 1999; Doksani et al., 2013).”
BackgroundTelomerase Reverse Transcriptase Delays Aging in Cancer-Resistant Mice
Tomás-Loba, A., Flores, I., Fernández-Marcos, P. J., Cayuela, M. L., Maraver, A., Tejera, A., Borrás, C., Matheu, A., Klatt, P., Flores, J. M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.09.034 · Cited by 484 · cited 1×
“However, and in support of critical telomere shortening being a determinant of aging and longevity, increased TERT expression in the context of cancer-resistant transgenic mice was sufficient to delay aging and extend mouse longevity by 40% (Tomás-Loba et al., 2008).”
BackgroundSelf-citationDisease states associated with telomerase deficiency appear earlier in mice with short telomeres
Herrera, E., Samper, E., Martín‐Caballero, J., Flores, J. M., Lee, H., & Blasco, M. A. (1999) · The EMBO Journal · doi:10.1093/emboj/18.11.2950 · Cited by 471 · cited 3×
“…the study of telomerase-deficient mice, which show premature aging phenotypes in both lowproliferating (heart, brain) and high-proliferating compartments (bone marrow [BM], gut, skin, and testis; Blasco et al., 1997; Lee et al., 1998; Herrera et al., 1999; Leri et al., 2003; Ferrón et al., 2004).”
BackgroundSelf-citationStuart, B. D., Choi, J., Zaidi, S., Xing, C., Holohan, B., Chen, R., Choi, M., Dharwadkar, P., Torres, F., Girod, C. E., et al. (2015) · Nature Genetics · doi:10.1038/ng.3278 · Cited by 469
Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins
Martínez, P., & Blasco, M. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3025 · Cited by 468 · cited 3×
“…mouse models of telomere dysfunction in combination with loss-of-function mutations in tumor suppressor genes strongly underscore the statement that telomere dysfunction leads to genomic rearrangements that are permissive for cancer initiation and progression (Table 2; Martínez and Blasco, 2011).”
BackgroundSelf-citationIn vivo loss of telomeric repeats with age in humans
Lindsey, J., McGill, N. I., Lindsey, L. A., Green, D. K., & Cooke, H. J. (1991) · Mutation Research/DNAging · doi:10.1016/0921-8734(91)90032-7 · Cited by 463 · cited 2×
“…to counteract telomere attrition associated with cell division throughout life, and therefore telomeres shorten with age in vitro and in vivo (Harley et al., 1990; Hastie et al., 1990; Lindsey et al., 1991; Collado et al., 2007; Liu et al., 2007; Flores et al., 2008; Marion et al., 2009).”
BackgroundTelomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells
Marion, R. M., Strati, K., Li, H., Tejera, A., Schoeftner, S., Ortega, S., Serrano, M., & Blasco, M. A. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2008.12.010 · Cited by 461 · cited 3×
“…to counteract telomere attrition associated with cell division throughout life, and therefore telomeres shorten with age in vitro and in vivo (Harley et al., 1990; Hastie et al., 1990; Lindsey et al., 1991; Collado et al., 2007; Liu et al., 2007; Flores et al., 2008; Marion et al., 2009).”
BackgroundSelf-citationPTOP interacts with POT1 and regulates its localization to telomeres
Liu, D., Safari, A., O'Connor, M. S., Chan, D. W., Laegeler, A., Qin, J., & Songyang, Z. (2004) · Nature Cell Biology · doi:10.1038/ncb1142 · Cited by 450 · cited 2×
“Although the telomeric phenotypes induced by these mutations have not been addressed, the observation that four of the five mutations found in TPP1 clustered in the POT1-binding domain suggests that POT1 recruitment to telomeres is disrupted, thereby causing similar phenotypes as observed in POT1 variants discussed ea…”
BackgroundEffects of Telomerase and Telomere Length on Epidermal Stem Cell Behavior
Flores, I., Cayuela, M. L., & Blasco, M. A. (2005) · Science · doi:10.1126/science.1115025 · Cited by 448 · cited 2×
“Both TERT and TRF1 deficiencies were previously shown to lead to a decreased ability of stem cells to regenerate tissues (Flores et al., 2005; Schneider et al., 2013).”
BackgroundSelf-citationThe causes and consequences of polyploidy in normal development and cancer
Davoli, T., & de Lange, T. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154234 · Cited by 424
Danazol Treatment for Telomere Diseases
Townsley, D. M., Dumitriu, B., Liu, D., Biancotto, A., Weinstein, B., Chen, C., Hardy, N., Mihalek, A. D., Lingala, S., Kim, Y. J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515319 · Cited by 415
Savage, S. A., Giri, N., Baerlocher, G. M., Orr, N., Lansdorp, P. M., & Alter, B. P. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.10.004 · Cited by 414 · cited 2×
“The TRF1-interacting shelterin protein TIN2 has also been found to be mutated in telomere syn- dromes (Savage et al., 2008; Alder et al., 2015b; Hoffman et al., 2016).”
BackgroundTelomere lengthening early in development
Liu, L., Bailey, S. M., Okuka, M., Muñoz, P., Li, C., Zhou, L., Wu, C., Czerwiec, E., Sandler, L., Seyfang, A., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1664 · Cited by 395 · cited 3×
“…to counteract telomere attrition associated with cell division throughout life, and therefore telomeres shorten with age in vitro and in vivo (Harley et al., 1990; Hastie et al., 1990; Lindsey et al., 1991; Collado et al., 2007; Liu et al., 2007; Flores et al., 2008; Marion et al., 2009).”
BackgroundSelf-citationGoing against the grain: chemotaxis and infection in Vibrio cholerae
Butler, S. M., & Camilli, A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1207 · Cited by 393
POT1 loss-of-function variants predispose to familial melanoma
Robles-Espinoza, C. D., Harland, M., Ramsay, A. J., Aoude, L. G., Quesada, V., Ding, Z., Pooley, K. A., Pritchard, A. L., Tiffen, J. C., Petljak, M., et al. (2014) · Nature Genetics · doi:10.1038/ng.2947 · Cited by 391 · cited 2×
“…to familial melanoma, familial glioma, Li-Fraumeni–like syndrome, mantle cell lymphoma, parathyroid adenoma, and chronic lymphocytic leukemia (Newey et al., 2012; Ramsay et al., 2013; Bainbridge et al., 2014; Robles-Espinoza et al., 2014; Shi et al., 2014; Zhang et al., 2014; Calvete et al., 2015).”
BackgroundEvidence that genetic instability occurs at an early stage of colorectal tumorigenesis.
Shih, I., Zhou, W. J., Goodman, S. N., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (2001) · PubMed · Cited by 385
The two-stage mechanism controlling cellular senescence and immortalization
Wright, W. E., & Shay, J. W. (1992) · Experimental Gerontology · doi:10.1016/0531-5565(92)90069-c · Cited by 383 · cited 1×
“In mammalian cells, replicative senescence can be bypassed by acquisition of loss-of-function mutations in tumor suppressor genes that permit further proliferation during a period of time that has been named the extended life span period (Fig. 3 C; Wright and Shay, 1992; Shay and Wright, 2005; Shay, 2016).”
BackgroundMartínez, P., Thanasoula, M., Muñoz, P., Liao, C., Tejera, A., McNees, C., Flores, J. M., Fernández-Capetillo, O., Tarsounas, M., & Blasco, M. A. (2009) · Genes & Development · doi:10.1101/gad.543509 · Cited by 370 · cited 9×
“Thus, Trf1lox/lox K5-cre p53−/− mice lacking TRF1 in stratified epithelia spontaneously develop invasive and genetically unstable squamous cell carcinomas in the tail and ear skin (Martínez et al., 2009b).”
BackgroundInfluentialSelf-citationShort Dysfunctional Telomeres Impair Tumorigenesis in the INK4aΔ2/3 Cancer-Prone Mouse
Greenberg, R. A., Chin, L., Femino, A., Lee, K.-H., Gottlieb, G. J., Singer, R. H., Greider, C. W., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80761-8 · Cited by 367
Calado, R. T., Yewdell, W. T., Wilkerson, K. L., Regal, J. A., Kajigaya, S., Stratakis, C. A., & Young, N. S. (2009) · Blood · doi:10.1182/blood-2008-09-178871 · Cited by 363 · cited 6×
“It was subsequently reported that sex hormones activate TERT transcription (Calado et al., 2009b).”
BackgroundInfluentialThe longest telomeres: a general signature of adult stem cell compartments
Flores, I., Canela, A., Vera, E., Tejera, A., Cotsarelis, G., & Blasco, M. A. (2008) · Genes & Development · doi:10.1101/gad.451008 · Cited by 352 · cited 4×
“Telomere shortening with age has also been observed in several mouse stem cell compartments from different tissues independently of high or low tissue proliferation rates (Flores et al., 2008).”
BackgroundInfluentialSelf-citationde Jesus, B. B., Schneeberger, K., Vera, E., Tejera, A., Harley, C. B., & Blasco, M. A. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00700.x · Cited by 348 · cited 2×
“…activators of telomerase or telomerase-based gene therapy are currently being investigated in mouse models for their potential to improve health and extend life span, and as a treatment for short telomere syndromes (Bernardes de Jesus et al., 2011; Bär et al., 2014, 2015; Bär and Blasco, 2016).”
BackgroundSelf-citationTelomerase-deficient mice with short telomeres are resistant to skin tumorigenesis
González-Suárez, E., Samper, E., Flores, J. M., & Blasco, M. A. (2000) · Nature Genetics · doi:10.1038/79089 · Cited by 347 · cited 2×
“…the K-Ras+/G12D lung tumorigenesis mouse model, showed antitumorigenic activity only after several mouse generations in the absence of telomerase when telomeres reached a critically short length (Chin et al., 1999; Greenberg et al., 1999; González-Suárez et al., 2000; Perera et al., 2008).”
BackgroundSelf-citationTelomere dysfunction causes alveolar stem cell failure
Alder, J. K., Barkauskas, C. E., Limjunyawong, N., Stanley, S. E., Kembou, F., Tuder, R. M., Hogan, B. L. M., Mitzner, W., & Armanios, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504780112 · Cited by 339 · cited 3×
“…mice induces senescence in alveolar progenitor cells and recapitulates the regenerative defects, inflammatory responses, and susceptibility to injury that are characteristic of human telomere-mediated lung disease, although no IPF was reported in these mouse models (Alder et al., 2015a).”
BackgroundRare missense variants in POT1 predispose to familial cutaneous malignant melanoma
NCI DCEG Cancer Sequencing Working Group, Shi, J., Laboratory, N. D. C. G. R., French Familial Melanoma Study Group, Yang, X. R., Ballew, B., Rotunno, M., Calista, D., Fargnoli, M. C., Ghiorzo, P., et al. (2014) · Nature Genetics · doi:10.1038/ng.2941 · Cited by 331
Robin, J. D., Ludlow, A. T., Batten, K., Magdinier, F., Stadler, G., Wagner, K. R., Shay, J. W., & Wright, W. E. (2014) · Genes & Development · doi:10.1101/gad.251041.114 · Cited by 328
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Tefferi, A., Lasho, T. L., Begna, K. H., Patnaik, M. M., Zblewski, D. L., Finke, C. M., Laborde, R. R., Wassie, E., Schimek, L., Hanson, C. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1310523 · Cited by 325 · cited 3×
“…most tumor types support the hypothesis that telomerase reactivation occurs at early time points during neoplastic transformation (Kinde et al., 2013; Allory et al., 2014; Hurst et al., 2014; Baerlocher et al., 2015; Chan et al., 2015; Huang et al., 2015; Tefferi et al., 2015; Jafri et al., 2016).”
BackgroundLeri, A., Franco, S., Zacheo, A., Barlucchi, L., Chimenti, S., Limana, F., Nadal‐Ginard, B., Kajstura, J., Anversa, P., & Blasco, M. A. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg013 · Cited by 313 · cited 1×
“…the study of telomerase-deficient mice, which show premature aging phenotypes in both lowproliferating (heart, brain) and high-proliferating compartments (bone marrow [BM], gut, skin, and testis; Blasco et al., 1997; Lee et al., 1998; Herrera et al., 1999; Leri et al., 2003; Ferrón et al., 2004).”
BackgroundSelf-citationTelomere Length Abnormalities Occur Early in the Initiation of Epithelial Carcinogenesis
Meeker, A. K., Hicks, J. L., Iacobuzio-Donahue, C. A., Montgomery, E. A., Westra, W. H., Chan, T. Y., Ronnett, B. M., & De Marzo, A. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0984-03 · Cited by 306 · cited 2×
“…analyses in a broad range of human tumor types at early stages underpin telomere crisis as a key event driving genomic instability and clonal evolution during progression to malignancy (Shih et al., 2001; Meeker et al., 2004; Lin et al., 2010; Davoli and de Lange, 2011; Roger et al., 2013).”
BackgroundDoes a Sentinel or a Subset of Short Telomeres Determine Replicative Senescence?
Zou, Y., Sfeir, A., Gryaznov, S. M., Shay, J. W., & Wright, W. E. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-03-0207 · Cited by 293 · cited 1×
“Shortened telomeres induce a DDR that leads to a growth arrest, during which cells attempt to repair the damage and, if DNA damage is irreparable, triggers replicative senescence (Zou et al., 2004; Fumagalli et al., 2012).”
BackgroundAllory, Y., Beukers, W., Sagrera, A., Flández, M., Marqués, M., Márquez, M., van der Keur, K. A., Dyrskjot, L., Lurkin, I., Vermeij, M., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.08.052 · Cited by 284 · cited 2×
“…most tumor types support the hypothesis that telomerase reactivation occurs at early time points during neoplastic transformation (Kinde et al., 2013; Allory et al., 2014; Hurst et al., 2014; Baerlocher et al., 2015; Chan et al., 2015; Huang et al., 2015; Tefferi et al., 2015; Jafri et al., 2016).”
BackgroundLoss of Rap1 Induces Telomere Recombination in the Absence of NHEJ or a DNA Damage Signal
Sfeir, A., Kabir, S., van Overbeek, M., Celli, G. B., & de Lange, T. (2010) · Science · doi:10.1126/science.1185100 · Cited by 278
Fogarty, P. F., Yamaguchi, H., Wiestner, A., Baerlocher, G. M., Sloand, E., Zeng, W. S., Read, E. J., Lansdorp, P. M., & Young, N. S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14797-6 · Cited by 277 · cited 2×
“Clinical features of telomeropathies Aplastic anemia: Aplastic anemia is a BM failure state characterized by low blood counts and an insufficiency of hematopoietic cells in the BM (Fogarty et al., 2003).”
BackgroundPOT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia
Ramsay, A. J., Quesada, V., Foronda, M., Conde, L., Martínez-Trillos, A., Villamor, N., Rodríguez, D., Kwarciak, A., Garabaya, C., Gallardo, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2584 · Cited by 276 · cited 2×
“…to familial melanoma, familial glioma, Li-Fraumeni–like syndrome, mantle cell lymphoma, parathyroid adenoma, and chronic lymphocytic leukemia (Newey et al., 2012; Ramsay et al., 2013; Bainbridge et al., 2014; Robles-Espinoza et al., 2014; Shi et al., 2014; Zhang et al., 2014; Calvete et al., 2015).”
BackgroundSelf-citationTelomere Length Is a Determinant of Emphysema Susceptibility
Alder, J. K., Guo, N., Kembou, F., Parry, E. M., Anderson, C. J., Gorgy, A. I., Walsh, M. F., Sussan, T., Biswal, S., Mitzner, W., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0520oc · Cited by 265 · cited 1×
“Exposure to cigarette smoke, which is known to accelerate PF onset in humans, induces emphysema but not PF in telomerase-deficient mice (Alder et al., 2011).”
BackgroundSpontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions
Cesare, A. J., Kaul, Z., Cohen, S. B., Napier, C. E., Pickett, H. A., Neumann, A. A., & Reddel, R. R. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1725 · Cited by 263 · cited 1×
“…point, named the intermediate telomere state, telomeres are too short to be fully functional and are presumably unable to form the T-loop structure but retain sufficient protective shelterin to inhibit end-to-end fusions (Cesare et al., 2009, 2013; Kaul et al., 2011; Cesare and Karlseder, 2012).”
BackgroundMartinez, P., Thanasoula, M., Carlos, A. R., Gómez-López, G., Tejera, A. M., Schoeftner, S., Dominguez, O., Pisano, D. G., Tarsounas, M., & Blasco, M. A. (2010) · Nature Cell Biology · doi:10.1038/ncb2081 · Cited by 257 · cited 3×
“A possible explanation for the role of RAP1 in cancer could be either through its role in repressing homology-directed repair at telomeres (Martinez et al., 2010; Sfeir et al., 2010) or through its role in telomere maintenance in the absence of telomerase (Martínez et al.”
BackgroundSelf-citationA Spectrum of Severe Familial Liver Disorders Associate with Telomerase Mutations
Calado, R. T., Regal, J. A., Kleiner, D. E., Schrump, D. S., Peterson, N. R., Pons, V., Chanock, S. J., Lansdorp, P. M., & Young, N. S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007926 · Cited by 254 · cited 7×
“It was subsequently reported that sex hormones activate TERT transcription (Calado et al., 2009b).”
BackgroundInfluentialKinde, I., Munari, E., Faraj, S. F., Hruban, R. H., Schoenberg, M., Bivalacqua, T., Allaf, M., Springer, S., Wang, Y., Diaz, L. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2498 · Cited by 253 · cited 2×
“…carcinogenesis in most tumor types support the hypothesis that telomerase reactivation occurs at early time points during neoplastic transformation (Kinde et al., 2013; Allory et al., 2014; Hurst et al., 2014; Baerlocher et al., 2015; Chan et al., 2015; Huang et al., 2015; Tefferi et al., 2015;…”
BackgroundDavoli, T., & de Lange, T. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.044 · Cited by 242
Telomere length is associated with disease severity and declines with age in dyskeratosis congenita
Alter, B. P., Rosenberg, P. S., Giri, N., Baerlocher, G. M., Lansdorp, P. M., & Savage, S. A. (2012) · Haematologica · doi:10.3324/haematol.2011.055269 · Cited by 238 · cited 1×
“Telomeres in HHS patients are shorter than those of age-matched patients with classic DC (Alter et al., 2012).”
ResultZhang, J., Jima, D., Moffitt, A. B., Liu, Q., Czader, M., Hsi, E. D., Fedoriw, Y., Dunphy, C. H., Richards, K. L., Gill, J. I., et al. (2014) · Blood · doi:10.1182/blood-2013-07-517177 · Cited by 236
Germline Mutations in Shelterin Complex Genes Are Associated With Familial Glioma
Bainbridge, M. N., Armstrong, G. N., Gramatges, M. M., Bertuch, A. A., Jhangiani, S. N., Doddapaneni, H., Lewis, L., Tombrello, J., Tsavachidis, S., Liu, Y., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju384 · Cited by 227 · cited 2×
“…to familial melanoma, familial glioma, Li-Fraumeni–like syndrome, mantle cell lymphoma, parathyroid adenoma, and chronic lymphocytic leukemia (Newey et al., 2012; Ramsay et al., 2013; Bainbridge et al., 2014; Robles-Espinoza et al., 2014; Shi et al., 2014; Zhang et al., 2014; Calvete et al., 2015).”
BackgroundMice with Pulmonary Fibrosis Driven by Telomere Dysfunction
Povedano, J. M., Martinez, P., Flores, J. M., Mulero, F., & Blasco, M. A. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.028 · Cited by 225 · cited 3×
“In one of them, treatment of late-generation telomerase-deficient mice presenting short telomeres with low doses of bleomycin, which normally does not lead to PF in wild-type mice, results in full-blown progressive PF in telomerase-deficient mice (Povedano et al., 2015).”
BackgroundInfluentialSelf-citationFive dysfunctional telomeres predict onset of senescence in human cells
Kaul, Z., Cesare, A. J., Huschtscha, L. I., Neumann, A. A., & Reddel, R. R. (2012) · The EMBO Reports · doi:10.1038/embor.2011.227 · Cited by 225 · cited 4×
“3, A and B; Kaul et al., 2011).”
BackgroundInfluentialThe Rate of Increase of Short Telomeres Predicts Longevity in Mammals
Vera, E., Bernardes de Jesus, B., Foronda, M., Flores, J. M., & Blasco, M. A. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.08.023 · Cited by 217 · cited 1×
“In mice, it has been shown that the rate of increase in the percentage of short telomeres, rather than the rate of telomere shortening throughout life, is a significant predictor of life span (Vera et al., 2012).”
BackgroundSelf-citationStanley, S. E., Gable, D. L., Wagner, C. L., Carlile, T. M., Hanumanthu, V. S., Podlevsky, J. D., Khalil, S. E., DeZern, A. E., Rojas-Duran, M. F., Applegate, C. D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf7837 · Cited by 210 · cited 3×
“Mutations in telomere genes have been found in up to 25% of familial and 1–3% of sporadic IPF patients (Armanios et al., 2007; Alder et al., 2008; Cogan et al., 2015; Kannengiesser et al., 2015; Stuart et al., 2015; Stanley et al., 2016).”
BackgroundBallew, B. J., & Savage, S. A. (2013) · Expert Review of Hematology · doi:10.1586/ehm.13.23 · Cited by 209 · cited 1×
“Patients with DC are at very high risk of BM failure, PF, liver fibrosis, stenosis, premature hair graying, leukemia, and squamous cell cancer of the head, neck, or anogenital regions (Ballew and Savage, 2013).”
BackgroundMolecular mechanisms of activity and derepression of alternative lengthening of telomeres
Pickett, H. A., & Reddel, R. R. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3106 · Cited by 203 · cited 1×
“Reactivation of either telomerase activity or the alternative lengthening of telomeres (ALT) allows these premalignant cells to escape crisis, undergo unlimited divisions (immortalization), and evolve into a fully transformed cancerous state (Fig. 3 E; Pickett and Reddel, 2015; Shay, 2016).”
BackgroundTelomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
Baerlocher, G. M., Oppliger Leibundgut, E., Ottmann, O. G., Spitzer, G., Odenike, O., McDevitt, M. A., Röth, A., Daskalakis, M., Burington, B., Stuart, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503479 · Cited by 200 · cited 3×
“…most tumor types support the hypothesis that telomerase reactivation occurs at early time points during neoplastic transformation (Kinde et al., 2013; Allory et al., 2014; Hurst et al., 2014; Baerlocher et al., 2015; Chan et al., 2015; Huang et al., 2015; Tefferi et al., 2015; Jafri et al., 2016).”
BackgroundRare Variants in RTEL1 Are Associated with Familial Interstitial Pneumonia
Cogan, J. D., Kropski, J. A., Zhao, M., Mitchell, D. B., Rives, L., Markin, C., Garnett, E. T., Montgomery, K. H., Mason, W. R., McKean, D. F., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201408-1510oc · Cited by 196 · cited 1×
“Mutations in telomere genes have been found in up to 25% of familial and 1–3% of sporadic IPF patients (Armanios et al., 2007; Alder et al., 2008; Cogan et al., 2015; Kannengiesser et al., 2015; Stuart et al., 2015; Stanley et al., 2016).”
BackgroundHuang, D.-S., Wang, Z., He, X.-J., Diplas, B. H., Yang, R., Killela, P. J., Meng, Q., Ye, Z.-Y., Wang, W., Jiang, X.-T., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.010 · Cited by 193 · cited 2×
“…most tumor types support the hypothesis that telomerase reactivation occurs at early time points during neoplastic transformation (Kinde et al., 2013; Allory et al., 2014; Hurst et al., 2014; Baerlocher et al., 2015; Chan et al., 2015; Huang et al., 2015; Tefferi et al., 2015; Jafri et al., 2016).”
BackgroundNonsense Mutations in the Shelterin Complex Genes ACD and TERF2IP in Familial Melanoma
Aoude, L. G., Pritchard, A. L., Robles-Espinoza, C. D., Wadt, K., Harland, M., Choi, J., Gartside, M., Quesada, V., Johansson, P., Palmer, J. M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju408 · Cited by 187 · cited 1×
“Mutations in TPP1 and RAP1 have also been found to be associated with familial melanoma (Aoude et al., 2014).”
BackgroundExome Sequencing Identifies Mutant TINF2 in a Family With Pulmonary Fibrosis
Alder, J. K., Stanley, S. E., Wagner, C. L., Hamilton, M., Hanumanthu, V. S., & Armanios, M. (2015) · Chest · doi:10.1378/chest.14-1947 · Cited by 181 · cited 3×
“…mice induces senescence in alveolar progenitor cells and recapitulates the regenerative defects, inflammatory responses, and susceptibility to injury that are characteristic of human telomere-mediated lung disease, although no IPF was reported in these mouse models (Alder et al., 2015a).”
BackgroundTejera, Á. M., d’Alcontres, M. S., Thanasoula, M., Marión, R. M., Martínez, P., Liao, C., Flores, J. M., Tarsounas, M., & Blasco, M. A. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.03.011 · Cited by 178 · cited 3×
“Interestingly, complete TPP1 and p53 abrogation in stratified epithelia, the Tpp1lox/lox K5-cre p53−/− mouse model, does not lead to epithelial carcinomas, most likely because TPP1 is required to recruit telomerase to chromosome ends, mimicking the tumor-resistant phenotype of telomerase-deficient mice (Table 2; Tejer…”
BackgroundInfluentialSelf-citationLin, T. T., Letsolo, B. T., Jones, R. E., Rowson, J., Pratt, G., Hewamana, S., Fegan, C., Pepper, C., & Baird, D. M. (2010) · Blood · doi:10.1182/blood-2010-02-272104 · Cited by 178 · cited 2×
“…analyses in a broad range of human tumor types at early stages underpin telomere crisis as a key event driving genomic instability and clonal evolution during progression to malignancy (Shih et al., 2001; Meeker et al., 2004; Lin et al., 2010; Davoli and de Lange, 2011; Roger et al., 2013).”
BackgroundShahidi, N. T., & Diamond, L. K. (1961) · New England Journal of Medicine · doi:10.1056/nejm196105112641901 · Cited by 177 · cited 2×
“2; Shahidi and Diamond, 1961; Jaime-Pérez et al., 2011).”
BackgroundTelomeropathies: An emerging spectrum disorder
Holohan, B., Wright, W. E., & Shay, J. W. (2014) · Journal of Cell Biology · doi:10.1083/jcb.201401012 · Cited by 175 · cited 8×
“These syndromes are characterized by premature loss of the regenerative capacity of tissues, affecting tissues with both high and low proliferation rates (Armanios and Blackburn, 2012; Holohan et al., 2014).”
BackgroundInfluentialA telomere-dependent DNA damage checkpoint induced by prolonged mitotic arrest
Hayashi, M. T., Cesare, A. J., Fitzpatrick, J. A. J., Lazzerini-Denchi, E., & Karlseder, J. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2245 · Cited by 166
Calvete, O., Martinez, P., Garcia-Pavia, P., Benitez-Buelga, C., Paumard-Hernández, B., Fernandez, V., Dominguez, F., Salas, C., Romero-Laorden, N., Garcia-Donas, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9383 · Cited by 166 · cited 2×
“…to familial melanoma, familial glioma, Li-Fraumeni–like syndrome, mantle cell lymphoma, parathyroid adenoma, and chronic lymphocytic leukemia (Newey et al., 2012; Ramsay et al., 2013; Bainbridge et al., 2014; Robles-Espinoza et al., 2014; Shi et al., 2014; Zhang et al., 2014; Calvete et al., 2015).”
BackgroundSelf-citationHurst, C. D., Platt, F. M., & Knowles, M. A. (2013) · European Urology · doi:10.1016/j.eururo.2013.08.057 · Cited by 164 · cited 2×
“…most tumor types support the hypothesis that telomerase reactivation occurs at early time points during neoplastic transformation (Kinde et al., 2013; Allory et al., 2014; Hurst et al., 2014; Baerlocher et al., 2015; Chan et al., 2015; Huang et al., 2015; Tefferi et al., 2015; Jafri et al., 2016).”
BackgroundIs telomerase a viable target in cancer?
Buseman, C. M., Wright, W. E., & Shay, J. W. (2011) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2011.07.006 · Cited by 163 · cited 2×
“Indeed, telomerase activity is dispensable for transformation of cells with long telomeres (Seger et al., 2002), and studies with telomerase inhibitors indicate that they are effective preferentially in cells with short telomeres (Wang et al., 2004; Buseman et al., 2012).”
BackgroundHeterozygous RTEL1 mutations are associated with familial pulmonary fibrosis
Kannengiesser, C., Borie, R., Ménard, C., Réocreux, M., Nitschké, P., Gazal, S., Mal, H., Taillé, C., Cadranel, J., Nunes, H., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00040115 · Cited by 162 · cited 1×
“Mutations in telomere genes have been found in up to 25% of familial and 1–3% of sporadic IPF patients (Armanios et al., 2007; Alder et al., 2008; Cogan et al., 2015; Kannengiesser et al., 2015; Stuart et al., 2015; Stanley et al., 2016).”
BackgroundBär, C., de Jesus, B. B., Serrano, R., Tejera, A., Ayuso, E., Jimenez, V., Formentini, I., Bobadilla, M., Mizrahi, J., de Martino, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms6863 · Cited by 162 · cited 6×
“AAV9-Tert after infarct treatment led to lower fibrotic scarring of the heart and increased cardiac myocyte proliferation concomitant with transcriptional changes suggestive of a regenerative signature (Bär et al., 2014).”
BackgroundMethodInfluentialSelf-citationMender, I., Gryaznov, S., Dikmen, Z. G., Wright, W. E., & Shay, J. W. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0609 · Cited by 162 · cited 2×
“Treatment with 6-thio-dG leads to rapid cell death in most of the cancer cell lines assayed and to telomere dysfunction in in vivo xenograft models (Mender et al., 2015).”
BackgroundUnraveling the pathogenesis of Hoyeraal–Hreidarsson syndrome, a complex telomere biology disorder
Glousker, G., Touzot, F., Revy, P., Tzfati, Y., & Savage, S. A. (2015) · British Journal of Haematology · doi:10.1111/bjh.13442 · Cited by 159 · cited 7×
“The DC-associated mucocutaneous triad is also a trait of HHS (Glousker et al., 2015).”
BackgroundInfluentialTransformation of normal human cells in the absence of telomerase activation
Seger, Y. R., Garcı́a-Cao, M., Piccinin, S., Cunsolo, C. L., Doglioni, C., Blasco, M. A., Hannon, G. J., & Maestro, R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00183-6 · Cited by 159 · cited 2×
“Indeed, telomerase activity is dispensable for transformation of cells with long telomeres (Seger et al., 2002), and studies with telomerase inhibitors indicate that they are effective preferentially in cells with short telomeres (Wang et al., 2004; Buseman et al., 2012).”
BackgroundSelf-citationWhole-Exome Sequencing Studies of Nonhereditary (Sporadic) Parathyroid Adenomas
Newey, P. J., Nesbit, M. A., Rimmer, A. J., Attar, M., Head, R. T., Christie, P. T., Gorvin, C. M., Stechman, M., Gregory, L., Mihai, R., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2303 · Cited by 156 · cited 2×
“…linked to familial melanoma, familial glioma, Li-Fraumeni–like syndrome, mantle cell lymphoma, parathyroid adenoma, and chronic lymphocytic leukemia (Newey et al., 2012; Ramsay et al., 2013; Bainbridge et al., 2014; Robles-Espinoza et al., 2014; Shi et al., 2014; Zhang et al., 2014; Calvete et…”
BackgroundThe Telomere Deprotection Response Is Functionally Distinct from the Genomic DNA Damage Response
Cesare, A. J., Hayashi, M. T., Crabbe, L., & Karlseder, J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.06.006 · Cited by 155 · cited 1×
“…point, named the intermediate telomere state, telomeres are too short to be fully functional and are presumably unable to form the T-loop structure but retain sufficient protective shelterin to inhibit end-to-end fusions (Cesare et al., 2009, 2013; Kaul et al., 2011; Cesare and Karlseder, 2012).”
BackgroundFerrón, S., Mira, H., Franco, S., Cano-Jaimez, M., Bellmunt, E., Ramírez, C., Fariñas, I., & Blasco, M. A. (2004) · Development · doi:10.1242/dev.01215 · Cited by 152 · cited 1×
“…the study of telomerase-deficient mice, which show premature aging phenotypes in both lowproliferating (heart, brain) and high-proliferating compartments (bone marrow [BM], gut, skin, and testis; Blasco et al., 1997; Lee et al., 1998; Herrera et al., 1999; Leri et al., 2003; Ferrón et al., 2004).”
BackgroundSelf-citationTRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells
Biroccio, A., Cherfils‐Vicini, J., Augereau, A., Pinte, S., Bauwens, S., Ye, J., Simonet, T., Horard, B., Jamet, K., Cervera, L., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2774 · Cited by 149 · cited 1×
“One possible explanation could be that high level of TRF2 in tumor cells decreases their ability to recruit and activate natural killer cells, thereby contributing to the bypass of innate immunosurveillance (Biroccio et al., 2013).”
BackgroundTelomere position effect regulates DUX4 in human facioscapulohumeral muscular dystrophy
Stadler, G., Rahimov, F., King, O. D., Chen, J. C. J., Robin, J. D., Wagner, K. R., Shay, J. W., Emerson, C. P., & Wright, W. E. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2571 · Cited by 139
Role of shelterin in cancer and aging
Martínez, P., & Blasco, M. A. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00596.x · Cited by 136 · cited 3×
“…tetraploidization, nonreciprocal translocations, chromothripsis, and kataegis, which promote acquisition of oncogenic mutations and malignant traits required for a fully malignant phenotype (Artandi and DePinho, 2010; Martínez and Blasco, 2010; Davoli and de Lange, 2012; Maciejowski et al., 2015).”
BackgroundSelf-citationEngineered telomere degradation models dyskeratosis congenitaPreprint
Hockemeyer, D. F., Palm, W., Wang, R. C., Couto, S. S., & de Lange, T. (2008) · Genes & Development · doi:10.1101/gad.1679208 · Cited by 129 · cited 3×
“…conditional knockout mouse models have recently served as proofs-of-principle of the causal role of DNA damage stemming from dysfunctional telomeres in DC, idiopathic PF (IPF), and aplastic anemia (see text box; Hockemeyer et al., 2008; He et al., 2009; Martínez et al., 2009b; Beier et al., 2012).”
BackgroundCell death during crisis is mediated by mitotic telomere deprotection
Hayashi, M. T., Cesare, A. J., Rivera, T., & Karlseder, J. (2015) · Nature · doi:10.1038/nature14513 · Cited by 125 · cited 1×
“3 D; Hayashi et al., 2012, 2015).”
The short and long telomere syndromes: paired paradigms for molecular medicine
Stanley, S. E., & Armanios, M. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.06.004 · Cited by 124
Telomere Replication Stress Induced by POT1 Inactivation Accelerates Tumorigenesis
Pinzaru, A. M., Hom, R. A., Beal, A., Phillips, A. F., Ni, E., Cardozo, T. J., Nair, N., Choi, J., Wuttke, D. S., Sfeir, A. J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.008 · Cited by 124 · cited 13×
“Attenuation of the ATR kinase pathway allows cancer cells lacking POT1 to proliferate, suggesting that POT1-mediated tumorigenesis may be accompanied by concomitant compensatory mechanisms that down-regulate the ATR-dependent DDR (Pinzaru et al., 2016).”
BackgroundInfluentialTelomeres and telomerase as therapeutic targets to prevent and treat age-related diseases
Bär, C., & Blasco, M. A. (2016) · F1000Research · doi:10.12688/f1000research.7020.1 · Cited by 123 · cited 4×
“In this regard, therapeutic interventions based on telomerase-based gene therapy are currently being investigated in mouse models for their potential to improve health and extend life span, and as a treatment for short telomere syndromes (Bär and Blasco, 2016).”
BackgroundInfluentialSelf-citationTransient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells
Ramunas, J., Yakubov, E., Brady, J. J., Corbel, S. Y., Holbrook, C., Brandt, M., Stein, J., Santiago, J. G., Cooke, J. P., & Blau, H. M. (2015) · The FASEB Journal · doi:10.1096/fj.14-259531 · Cited by 119 · cited 2×
“2; Ramunas et al., 2015).”
MethodTERT promoter mutations contribute to subset prognostication of lower-grade gliomas
Chan, A. K., Yao, Y., Zhang, Z., Chung, N. Y., Liu, J. S.-M., Li, K. K., Shi, Z., Chan, D. T. M., Poon, W. S., Zhou, L., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.94 · Cited by 118 · cited 2×
“…most tumor types support the hypothesis that telomerase reactivation occurs at early time points during neoplastic transformation (Kinde et al., 2013; Allory et al., 2014; Hurst et al., 2014; Baerlocher et al., 2015; Chan et al., 2015; Huang et al., 2015; Tefferi et al., 2015; Jafri et al., 2016).”
BackgroundBär, C., Povedano, J. M., Serrano, R., Benitez-Buelga, C., Popkes, M., Formentini, I., Bobadilla, M., Bosch, F., & Blasco, M. A. (2016) · Blood · doi:10.1182/blood-2015-08-667485 · Cited by 116 · cited 1×
“Indeed, by using the mouse preclinical model of aplastic anemia provoked by short telomeres in the BM, we demonstrate that AVV9-Tert rescues aplastic anemia and mouse survival by inducing telomere lengthening in peripheral blood and BM cells as well as increasing blood counts (Bär et al., 2016).”
Self-citationHe, H., Wang, Y., Guo, X., Ramchandani, S., Ma, J., Shen, M., Garcia, D. A., Deng, Y., Multani, A. S., You, M. J., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01400-08 · Cited by 110 · cited 3×
“…conditional knockout mouse models have recently served as proofs-of-principle of the causal role of DNA damage stemming from dysfunctional telomeres in DC, idiopathic PF (IPF), and aplastic anemia (see text box; Hockemeyer et al., 2008; He et al., 2009; Martínez et al., 2009b; Beier et al., 2012).”
BackgroundA three-state model of telomere control over human proliferative boundaries
Cesare, A. J., & Karlseder, J. (2012) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2012.08.007 · Cited by 106 · cited 1×
“At that point, named the intermediate telomere state, telomeres are too short to be fully functional and are presumably unable to form the T-loop structure but retain sufficient protective shelterin to inhibit end-to-end fusions (Cesare et al., 2009, 2013; Kaul et al., 2011; Cesare and Karlseder, 2012).”
BackgroundNakanishi, K., Kawai, T., Kumaki, F., Hiroi, S., Mukai, M., Ikeda, E., Koering, C., & Gilson, É. (2003) · PubMed · Cited by 101
Harley, C. B., Liu, W., Flom, P. L., & Raffaele, J. M. (2013) · Rejuvenation Research · doi:10.1089/rej.2013.1430 · Cited by 100 · cited 2×
“Telomeres as therapeutic targets • martínez and Blasco 879 TA-65 has been shown to lead to moderate telomere lengthening and improvement of some aging-related parameters in mice and humans, although no effect on longevity has been observed (Fig. 2; Bernardes de Jesus et al., 2011; Harley et al., 2013).”
BackgroundMutant Mice Lacking the p53 C-Terminal Domain Model Telomere Syndromes
Simeonova, I., Jaber, S., Drašković, I., Bardot, B., Fang, M., Bouarich-Bourimi, R., Lejour, V., Charbonnier, L., Soudais, C., Bourdon, J., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.05.028 · Cited by 97 · cited 6×
“Indeed, to our knowledge, the only mouse mutant that faithfully models human HHS does not harbor mutations in any of the known telomere maintenance genes associated with these diseases, but rather a mutation in TP53 gene (Simeonova et al., 2013).”
BackgroundInfluentialRoger, L., Jones, R. E., Heppel, N. H., Williams, G. T., Sampson, J. R., & Baird, D. M. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt191 · Cited by 97 · cited 2×
“…analyses in a broad range of human tumor types at early stages underpin telomere crisis as a key event driving genomic instability and clonal evolution during progression to malignancy (Shih et al., 2001; Meeker et al., 2004; Lin et al., 2010; Davoli and de Lange, 2011; Roger et al., 2013).”
BackgroundTRF1 is a stem cell marker and is essential for the generation of induced pluripotent stem cells
Schneider, R. P., Garrobo, I., Foronda, M., Palacios, J., Marión, R. M., Flores, I., Ortega, S., & Blasco, M. A. (2013) · Nature Communications · doi:10.1038/ncomms2946 · Cited by 92 · cited 4×
“Both TERT and TRF1 deficiencies were previously shown to lead to a decreased ability of stem cells to regenerate tissues (Flores et al., 2005; Schneider et al., 2013).”
BackgroundInfluentialSelf-citationVarela, E., Schneider, R. P., Ortega, S., & Blasco, M. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105414108 · Cited by 90 · cited 1×
“Interestingly, TRF1 is highly expressed in pluripotent stem cells and adult stem cells (Boué et al., 2010; Varela et al., 2011; Schneider et al., 2013).”
BackgroundSelf-citationWang, E. S., Wu, K., Chin, A. C., Chen-Kiang, S., Pongracz, K., Gryaznov, S., & Moore, M. A. S. (2004) · Blood · doi:10.1182/blood-2003-02-0546 · Cited by 84 · cited 2×
“Indeed, telomerase activity is dispensable for transformation of cells with long telomeres (Seger et al., 2002), and studies with telomerase inhibitors indicate that they are effective preferentially in cells with short telomeres (Wang et al., 2004; Buseman et al., 2012).”
BackgroundBar, C., Huber, N., Beier, F., & Blasco, M. A. (2015) · Haematologica · doi:10.3324/haematol.2015.129239 · Cited by 81 · cited 3×
“…activators of telomerase or telomerase-based gene therapy are currently being investigated in mouse models for their potential to improve health and extend life span, and as a treatment for short telomere syndromes (Bernardes de Jesus et al., 2011; Bär et al., 2014, 2015; Bär and Blasco, 2016).”
BackgroundSelf-citationBeier, F., Foronda, M., Martinez, P., & Blasco, M. A. (2012) · Blood · doi:10.1182/blood-2012-03-418038 · Cited by 79 · cited 5×
“JCB • Volume 216 • NumBer 4 • 2017 878 cell and progenitor compartments (hematopoietic stem/progenitor cells [HSPCs]) or by transplanting irradiated wildtype mice with BM from late-generation telomerase-deficient Tert knockout mice presenting with short telomeres (Beier et al., 2012; Bär and Blasco, 2016).”
BackgroundInfluentialSelf-citationDanazol as first-line therapy for aplastic anemia
Jaime‐Pérez, J. C., Colunga-Pedraza, P. R., Gómez-Ramírez, C. D., Gutiérrez‐Aguirre, C. H., Cantú‐Rodríguez, O. G., Tarin-Arzaga, L. C., & Gómez‐Almaguer, D. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1163-x · Cited by 68 · cited 2×
“2; Shahidi and Diamond, 1961; Jaime-Pérez et al., 2011).”
BackgroundVarela, E., Muñoz-Lorente, M. A., Tejera, A. M., Ortega, S., & Blasco, M. A. (2016) · Nature Communications · doi:10.1038/ncomms11739 · Cited by 67 · cited 3×
“…presenting hyperlong telomeres showed neither disadvantageous effects nor enhanced predisposition for cancer development compared with control chimeric mice presenting normal telomere length, indicating that long telomeres do not cause negative consequences to the organism (Varela et al., 2016).”
BackgroundInfluentialSelf-citationPerera, S. A., Maser, R. S., Xia, H., McNamara, K. L., Protopopov, A. I., Chen, L., Hezel, A. F., Kim, C. F., Bronson, R. T., Castrillón, D. H., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn050 · Cited by 65 · cited 2×
“…the K-Ras+/G12D lung tumorigenesis mouse model, showed antitumorigenic activity only after several mouse generations in the absence of telomerase when telomeres reached a critically short length (Chin et al., 1999; Greenberg et al., 1999; González-Suárez et al., 2000; Perera et al., 2008).”
BackgroundElse, T., Trovato, A., Kim, A. C., Wu, Y., Ferguson, D. O., Kuick, R. D., Lucas, P. C., & Hammer, G. D. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.011 · Cited by 62 · cited 4×
“Terc−/− p53−/− Earlier onset lymphoma/sarcoma, epithelial carcinoma Chin et al., 1999 Terc−/− Msh2−/− Lymphoma/carcinoma Martinez et al., 2009a Trf1lox/lox K5-cre p53−/− Squamous cell carcinoma Martínez et al., 2009b Pot1alox/lox p53lox/lox hCD2-iCre T cell lymphomas Pinzaru et al., 2016 Pot1alox/lox p53lox/lox Sprr2f…”
BackgroundInfluentialBoué, S., Paramonov, I., Barrero, M. J., & Belmonte, J. C. I. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012664 · Cited by 62 · cited 1×
“Interestingly, TRF1 is highly expressed in pluripotent stem cells and adult stem cells (Boué et al., 2010; Varela et al., 2011; Schneider et al., 2013).”
BackgroundPal, D., Sharma, U., Singh, S. K., Kakkar, N., & Prasad, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0115651 · Cited by 61 · cited 2×
“Several studies have reported up-regulation of the shelterin complex TRF1 and TRF2 in lung, gastric, breast, and renal cancers, suggesting that their overexpression might confer proliferative advantages to tumor cells (Miyachi et al., 2002; Saito et al., 2002; Nakanishi et al., 2003; Diehl et al., 2011; Pal et al., 20…”
BackgroundRecent Patents on Anti-Telomerase Cancer Therapy
Agrawal, A., Dang, S., & Gabrani, R. (2012) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489212798357958 · Cited by 61 · cited 2×
“Telomeres as therapeutic targets • martínez and Blasco 883 notherapy, gene therapy using telomerase promoter-driven expression of a suicide gene, and chemicals that block telomerase biogenesis (Harley, 2008; Agrawal et al., 2012; Buseman et al., 2012; Jafri et al., 2016).”
BackgroundGarcía‐Beccaria, M., Martínez, P., Méndez‐Pertuz, M., Martínez, S., Blanco‐Aparicio, C., Cañamero, M., Mulero, F., Ambrogio, C., Flores, J. M., Megias, D., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404497 · Cited by 55
Self-citationKhoo, C. M., Carrasco, D. R., Bosenberg, M. W., Paik, J.-H., & DePinho, R. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700093104 · Cited by 52 · cited 2×
“…Akbay et al., 2013 Tpp1Acd p53−/− Carcinomas Else et al., 2009 Tpp1lox/lox K5-cre p53−/− Cancer suppressor Tejera et al., 2010 Terc−/− Ink4a/Arf−/− Delayed lymphoma/fibrosarcoma onset Khoo et al., 2007 Trf1lox/lox p53−/− K-RasLSLG12V Growth impairment of lung…”
BackgroundGeorge, G., Rosas, I. O., Cui, Y., McKane, C. K., Hunninghake, G. M., Camp, P. C., Raby, B. A., Goldberg, H. J., & El‐Chemaly, S. (2014) · CHEST Journal · doi:10.1378/chest.14-0631 · Cited by 50
Elevated TRF2 in advanced breast cancers with short telomeres
Diehl, M. C., Idowu, M. O., Kimmelshue, K. N., York, T. P., Jackson‐Cook, C. K., Turner, K. C., Holt, S. E., & Elmore, L. W. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0988-7 · Cited by 48 · cited 2×
“Several studies have reported up-regulation of the shelterin complex TRF1 and TRF2 in lung, gastric, breast, and renal cancers, suggesting that their overexpression might confer proliferative advantages to tumor cells (Miyachi et al., 2002; Saito et al., 2002; Nakanishi et al., 2003; Diehl et al., 2011; Pal et al., 20…”
BackgroundMartínez, P., Gómez-López, G., Pisano, D. G., Flores, J. M., & Blasco, M. A. (2016) · Aging Cell · doi:10.1111/acel.12517 · Cited by 47 · cited 2×
“, 2010) or through its role in telomere maintenance in the absence of telomerase (Martínez et al., 2016).”
BackgroundSelf-citationMSH2 deficiency abolishes the anticancer and pro‐aging activity of short telomeres
Martínez, P., Siegl‐Cachedenier, I., Flores, J. M., & Blasco, M. A. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00441.x · Cited by 46 · cited 8×
“Thus, Trf1lox/lox K5-cre p53−/− mice lacking TRF1 in stratified epithelia spontaneously develop invasive and genetically unstable squamous cell carcinomas in the tail and ear skin (Martínez et al., 2009b).”
BackgroundInfluentialSelf-citationCorrelation between telomerase activity and telomeric-repeat binding factors in gastric cancer.
Miyachi, K., Fujita, M., Tanaka, N., Sasaki, K., & Sunagawa, M. (2002) · PubMed · Cited by 45
Saito, K., Yagihashi, A., Nasu, S., Izawa, Y., Nakamura, M., Kobayashi, D., Tsuji, N., & Watanabe, N. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb02166.x · Cited by 39 · cited 2×
“Several studies have reported up-regulation of the shelterin complex TRF1 and TRF2 in lung, gastric, breast, and renal cancers, suggesting that their overexpression might confer proliferative advantages to tumor cells (Miyachi et al., 2002; Saito et al., 2002; Nakanishi et al., 2003; Diehl et al., 2011; Pal et al., 20…”
BackgroundAkbay, E. A., Peña, C. G., Ruder, D., Michel, J., Nakada, Y., Pathak, S., Multani, A. S., Chang, S. S., & Castrillón, D. H. (2012) · Oncogene · doi:10.1038/onc.2012.232 · Cited by 38 · cited 3×
“…cell carcinoma Martínez et al., 2009b Pot1alox/lox p53lox/lox hCD2-iCre T cell lymphomas Pinzaru et al., 2016 Pot1alox/lox p53lox/lox Sprr2f-Cre Endometrial adenocarcinomas Akbay et al., 2013 Tpp1Acd p53−/− Carcinomas Else et al., 2009 Tpp1lox/lox K5-cre p53−/− Cancer…”
BackgroundShading the TRF2 Recruiting Function: A New Horizon in Drug Development
Maro, S. D., Zizza, P., Salvati, E., Luca, V. D., Capasso, C., Fotticchia, I., Pagano, B., Marinelli, L., Gilson, É., Novellino, E., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5080773 · Cited by 34 · cited 2×
“Treatment of HeLa cells with TRF2-binding chemotypes did not affect TRF2 telomeric localization but induced rapid DDR activation, end-to-end fusions, and cell death indicative of telomere dysfunction (Di Maro et al., 2014).”
BackgroundTINF2Gene Mutation in a Patient with Pulmonary Fibrosis
Hoffman, T. W., van der Vis, J. J., van Oosterhout, M. F. M., van Es, H. W., van Kessel, D. A., Grutters, J. C., & van Moorsel, C. H. M. (2016) · Case Reports in Pulmonology · doi:10.1155/2016/1310862 · Cited by 29 · cited 4×
“The TRF1-interacting shelterin protein TIN2 has also been found to be mutated in telomere syn- dromes (Savage et al., 2008; Alder et al., 2015b; Hoffman et al., 2016).”
BackgroundInfluential
Research works printed but not linked: 1
- Bär, 2016, F1000 Res, 89
Cited by
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
The central role of DNA damage in the ageing process
Schumacher, B., Pothof, J., Vijg, J., & Hoeijmakers, J. H. J. (2021) · Nature · doi:10.1038/s41586-021-03307-7 · Cited by 907
Telomere dysfunction in ageing and age-related diseases
Rossiello, F., Jurk, D., Passos, J. F., & d’Adda di Fagagna, F. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00842-x · Cited by 754
Molecular mechanisms of aging and anti-aging strategies
Li, Y., Tian, X., Luo, J., Bao, T., Wang, S., & Wu, X. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01663-1 · Cited by 293
“Excellent telomere and telomerase structures are essential for ensuring the normal physiological function of mothers and offspring, and their integrity has a certain genetic intergenerational effect [102, 103].”
BackgroundOxidative Stress in Pulmonary Fibrosis
Otoupalova, E., Smith, S., Cheng, G., & Thannickal, V. J. (2020) · Comprehensive Physiology · doi:10.1002/cphy.c190017 · Cited by 262
“Telomere shortening is associated with aging and age-related diseases, including IPF (20, 355, 376).”
Metadata
- Authors
- Martínez, P., & Blasco, M. A.
- Affiliations
- Spanish National Cancer Research Centre (ES)
- Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre, Madrid E-28029, Spain
- Venue
- Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2017-03-02
- Volume
- 216
- Issue
- 4
- Pages
- 875-887
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- PMC
- PMC5379954
- OpenAlex
- W2592919828
- Cited by
- 257
- References
- 148
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 22 · 2023: 21 · 2022: 33 · 2021: 43 · 2020: 38 · 2019: 21 · 2018: 33 · 2017: 13
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Cell Biology (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- Spanish Ministry of Economy and Competitiveness
- Fondo Europeo de Desarrollo Regional (SAF2013-45111-R)
- European Research Council (ERC-2008-AdG/232854)
- Fundación Botín
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Structure and Function
- Keywords
- telomeres, telomere shortening, aging, Hoyeraal-Hreidarsson syndrome, dyskeratosis congenita, pulmonary fibrosis, aplastic anemia, liver fibrosis, chromosomal instability, carcinogenesis, shelterin, telomere maintenance genes, cancer, stem cell proliferation, mouse model
- MeSH terms
- Aging, Animals, Cell Transformation, Neoplastic, Fetal Growth Retardation, Humans, Intellectual Disability, Microcephaly, Mutation, Neoplasms, Telomere, Telomerase, Dyskeratosis Congenita, Chromosomal Instability, Molecular Targeted Therapy, Telomere Homeostasis, Telomere Shortening
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.